ReviewStem cell reviews and reports2026
Cell Therapy as Metabolic Rescue after Ischemic Stroke: Rewiring Bioenergetics, Redox Homeostasis, and Neurovascular Repair.
Review in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke represents a dynamic metabolic disorder of the neurovascular unit (NVU) rather than a static vascular occlusion followed by neuronal demise. Immediate oxygen and glucose deprivation rapidly deplete ATP, disrupt the transmembrane ionic gradients, increase glutamate excitotoxicity, and overload mitochondrial with calcium. These events alter glycolytic, lipid, amino acid, and redox pathways. During the subacute and chronic phases, astrocytes, microglia, macrophages, endothelial cells, pericytes, oligodendrocytes, and surviving neurons continue to remodel substrate utilization. These phase-specific metabolic programs either accelerate infarct expansion and blood-brain barrier disruption or facilitate angiogenesis, synaptic plasticity, and tissue repair. Consequently, cell-based therapeutic paradigms have shifted from direct neuronal replacement toward metabolic rescue. Transplanted cells and cell-free derivatives deliver trophic factors, extracellular vesicles, microRNAs, antioxidant signals, mitochondrial cues, and immunoregulatory factors. These signals enhance mitochondrial fitness, restore redox homeostasis, attenuate pro-inflammatory glycolysis, and stabilize endothelial-pericyte coupling to stabilize a permissive neurorehabilitation microenvironment. This review synthesizes post-stroke metabolic landscapes and evaluates how mesenchymal stromal, neural stem/progenitor, endothelial progenitor, cord blood-derived, and mononuclear cells, and extracellular vesicles, may be incorporated into a phase-specific translational framework supported by target-engagement biomarkers and standardized potency assays.
Indexed as
Identifiers
42509439What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.